Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum

被引：3
|
作者：
Idowu, Oladipo S. [1 ]
Craigen, Jenny L. [2 ]
Veal, Gareth J. [1 ]
Jamieson, David [1 ]
机构：
[1] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne NE2 4HH, England
[2] Canc Res UK Ctr Drug Dev, London E20 1JQ, England
来源：
BIOANALYSIS | 2022年 / 14卷 / 18期
关键词：
assay validation; cancer; ELISA; HER3; pharmacokinetics; RECEPTOR HETERODIMERIZATION; ERBB3; EXPRESSION; GROWTH; CANCER; HER3;
D O I：
10.4155/bio-2022-0141
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: HMBD-001 is an IgG1 humanized monoclonal antibody specifically targeting HER3, a receptor highly expressed on cancer cells in certain tumors. A bioanalytical method was required to quantify HMBD-001 in human serum, with high selectivity and without interference from HER3. Methods and results: A bridging ELISA using an anti-idiotypic monoclonal capture and detection was developed and validated for quantitative measurement of HMBD-001 in human serum. The assay is sensitive, with a lower limit of quantification of 250 ng/ml, has a broad dynamic range of 250-7000 ng/ml HMBD-001, and exhibits excellent precision and overall accuracy. Conclusion: We have developed and validated a sensitive and selective method for measuring HMBD-001 in human serum. This assay is now being used in a clinical trial setting.
引用
收藏
页码：1241 / 1249
页数：9
相关论文
共 50 条
  • [31] Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application
    Lindahl, Sofia
    Dyrkorn, Roar
    Spigset, Olav
    Hegstad, Solfrid
    THERAPEUTIC DRUG MONITORING, 2018, 40 (03) : 369 - 376
  • [32] Development and Validation of a Method for Quantification of Lisinopril, Indapamide, Metoprolol, Valsartan, and Amoldipine in Human Blood Serum by HPLC-MS/MS
    Mylnikov, P. Yu.
    Shchulkin, A. V.
    Seleznev, S. V.
    Pravkin, S. K.
    Abalenikhina, Yu. V.
    Yakusheva, E. N.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2024, 58 (03) : 507 - 511
  • [33] Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue
    Roseboom, Ignace C.
    Thijssen, Bas
    Rosing, Hilde
    Alves, Fabiana
    Mondal, Dinesh
    Teunissen, Marcel B. M.
    Beijnen, Jos H.
    Dorlo, Thomas P. C.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 207
  • [34] Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium
    Roche, Sandra
    Sewell, Louise
    Meiller, Justine
    Pedersen, Kasper
    Rajpal, Rajesh
    O'Gorman, Peter
    Clynes, Martin
    O'Connor, Robert
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 902 : 16 - 26
  • [35] Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry
    Moreau, Megane
    Auger, Serge
    Picard, Pierre
    Lacoursiere, Jean
    Segura, Pedro A.
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2024, 38 (17)
  • [36] Development and validation of an LC-MS/MS based method for quantification of 25 hydroxyvitamin D2 and 25 hydroxyvitamin D3 in human serum and plasma
    Zhang, Stanley
    Jian, Wenying
    Sullivan, Sheryl
    Sankaran, Banu
    Edom, Richard W.
    Weng, Naidong
    Sharkey, David
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, 961 : 62 - 70
  • [37] Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer
    Kogawa, Takahiro
    Yonemori, Kan
    Naito, Yoichi
    Noguchi, Emi
    Shimizu, Chikako
    Tamura, Kenji
    Hosono, Ako
    Matsubara, Nobuaki
    Sugihara, Masahiro
    Ogawa, Hayao
    Majima, Shuji
    Yu, Channing
    Ueno, Suguru
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
    Shimizu, Toshio
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Haratani, Koji
    Yamada, Hironori
    Ohwada, Shoichi
    Kamiyama, Emi
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 489 - 495
  • [39] Development and Validation of an Adsorptive Stripping Voltammetric Method for the Quantification of Vincamine in Its Formulations and Human Serum Using a Nujol-Based Carbon Paste Electrode
    Beltagi, Amr Mohamed
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2008, 56 (12) : 1651 - 1657
  • [40] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
    Toshio Shimizu
    Kimio Yonesaka
    Hidetoshi Hayashi
    Tsutomu Iwasa
    Koji Haratani
    Hironori Yamada
    Shoichi Ohwada
    Emi Kamiyama
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 489 - 495
12345